[EN] SUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINE COMPOUNDS USEFUL AS CYP17 MODULATORS [FR] COMPOSÉS SUBSTITUÉS DE BENZIMIDAZOLE ET D'IMIDAZOPYRIDINE UTILES COMME MODULATEURS DE CYP17
[EN] SUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINE COMPOUNDS USEFUL AS CYP17 MODULATORS [FR] COMPOSÉS SUBSTITUÉS DE BENZIMIDAZOLE ET D'IMIDAZOPYRIDINE UTILES COMME MODULATEURS DE CYP17
SUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINE COMPOUNDS USEFUL AS CYP17 MODULATORS
申请人:Huang Audris
公开号:US20130310393A1
公开(公告)日:2013-11-21
Disclosed are heteroaryl compounds of Formula (I), (I), or pharmaceutically acceptable salts thereof, wherein Z is CH or N; W is CR
3
or N; and R
1
, R
2
, and R
3
are defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.
[EN] SUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINE COMPOUNDS USEFUL AS CYP17 MODULATORS<br/>[FR] COMPOSÉS SUBSTITUÉS DE BENZIMIDAZOLE ET D'IMIDAZOPYRIDINE UTILES COMME MODULATEURS DE CYP17
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2012044537A1
公开(公告)日:2012-04-05
Disclosed are heteroaryl compounds of Formula (I), (I), or pharmaceutically acceptable salts thereof, wherein Z is CH or N; W is CR3 or N; and R1, R2, and R3 are defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.